According to the Zhitong Finance App, Chengda Pharmaceutical (301201.SZ) released its report for the third quarter of 2026. In the first three quarters, the company achieved revenue of 356 million yuan, an increase of 24.76% over the previous year. The net loss attributable to shareholders of the listed company was 124.277 million yuan. Net loss of $22.119 million for non-recurring profit and loss attributable to shareholders of listed companies is deducted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.